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Abstract
Background: Near-infrared fluorescence (NIRF) imaging combined with enzyme-activatable NIRF probes has yielded promising
results in cancer detection.
Objective: To test whether 3-dimensional (3-D) noninvasive in vivo NIRF imaging can detect effects of epidermal growth factor
receptor (EGFR) inhibitor on both polypoid and flat tumor load in azoxymethane (AOM)-induced colon tumors or tumors in
ApcMin/þ mice.
Methods: The AOM-injected KK-HIJ mice received EGFR inhibitor diet or chow diet. These and ApcMin/þ mice were given
cathepsin-activatable probes (ProSense 680) before imaging. In vivo imaging was performed using quantitative tomographic NIRF
imaging. Ex vivo imaging and histologic examination were performed. Dual imaging by micro computed tomography (CT) and 3D
NIRF imaging was used to verify tumor location.
Results: Tumor load reduction by EGFR inhibition was detected ex vivo using cathepsin B probes. In vivo imaging revealed
intense activation of probes only in large tumors. Dual imaging with microCT and 3D NIRF imaging improved tumor detection in
vivo.
Conclusions: The 3-D NIRF imaging with ProSense 680 can detect and quantify drug effects on colon tumors ex vivo. The NIRF
imaging with ProSense 680 probe has limitations as a valid nonendoscopic method for intestinal tumor detection. Combing with
other imaging modalities will improve the specificity and sensitivity of intestinal tumor detection in vivo.
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Introduction
Colorectal cancer (CRC) is the second most common malig-
nancy in the developed world, and despite recent advances in
chemotherapeutics, this disease remains the third cause of mor-
bidity and mortality in the United States in both males and
females.1 In recent years, a rapid decline in the incidence rate
of CRC has largely been attributed to increased screening colo-
noscopy for detection and removal of precancerous polyps.1
However, miss rates of precancerous polyps and flat tumors
using traditional white light colonoscopy are still estimated at
around 20%.2-4 Contrast enhancement-based narrow-band ima-
ging modalities or other advanced endoscopic technologies,
such as high-definition colonoscopy and chromoendoscopy,
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have been extensively investigated but neither showed
improvement in detection of adenomas.5-7 Flat tumors are dif-
ficult to distinguish from background inflammation but are
biologically aggressive leading to higher mortality rates. Thus,
improved detection methods are desirable to maximize detec-
tion of small and flat colorectal lesions,8 quantitatively mea-
sure tumor size and number, and monitor drug effects,9 with the
ultimate goal of increasing the efficiency of endoscopic or
noninvasive screening procedures in clinical practice.
Compared to the white light used in traditional endo-
scopes, imaging at near-infrared fluorescence (NIRF) results
in less autofluorescence background, deeper tissue penetra-
tion, and reduced hemoglobin absorption10 and has success
in detection of colonic adenomas in preclinical models.10-13
Enzyme-activatable NIRF optical probes are a type of mole-
cular beacon. These probes are optically silent in their
uncleaved state and increase their fluorescence intensity
after enzyme-mediated cleavage of specific peptide
sequences due to elimination of fluorochrome quenching,
resulting in signal amplification at the site of probe clea-
vage.14,15 If the enzymes specific for the peptide sequence
in the NIRF probe are overexpressed in tumors, imaging
with these activatable probes could significantly increase
contrast between tumor and normal tissue and generate
higher target to background ratios.16
Cathepsins are proteases that actively participate in the
proteolytic degradation of the extracellular matrix. Cathe-
psin B is overexpressed in a number of cancers, including
colon cancer,17,18 providing a potentially valuable target
molecule for CRC detection and monitoring different stages
of colon carcinogenesis or response to cancer therapies.
Cathepsin-activatable NIRF probes have been used to detect
colon tumors in several colon tumor models including the
ApcMin/þ mouse model,19,20 mouse xenografts,11 which can-
not fully recapitulate the microadenoma–adenomas–adeno-
carcinoma progression,21, and the interleukin-10 null model,
as well as colitis-associated cancer and dysplasia.18,20,22 To
date, the use of NIRF imaging with cathepsin-activatable
probes to detect intestinal tumors has focused on ex vivo
fluorescence reflectance imaging (FRI). Recent studies18,19
combined white light and NIRF colonoscopy to demonstrate
that cathepsin-activatable probes successfully detected dys-
plastic foci in a mouse model of colitis-associated colon
cancer, indicating potential benefits of this methodology in
clinical endoscopy. However, few studies have tested the
utility of enzyme-activatable probes for monitoring or quan-
tification of colorectal tumor response to therapies. Such
approaches could provide significant benefit to preclinical
studies, where quantification of tumor load, particularly
small or flat lesions, is labor intensive. Moreover, there is
evidence for improved polyp detection by activatable NIRF
probes during colonoscopy in preclinical models.23,24 A
real-time in vivo nonendoscopic imaging of colon tumori-
genesis is highly desirable in preclinical models to provide
the potential for longitudinal noninvasive monitoring of the
same animal.
The current study tested the hypothesis that ex vivo or
in vivo 3-dimensional (3-D) noninvasive NIRF imaging
would reliably quantify tumor load in azoxymethane
(AOM)-induced tumors in KK-HIJ mice, which develop
primarily polypoid but also some flat lesions25 and would
be useful to detect and quantify the impact of epidermal
growth factor receptor (EGFR) inhibitor tyrphostin on
tumor load from both polypoid and flat tumors in a single
mouse model. We tested whether signal intensity corre-
lated with tumor size and whether small lesions detected
by probe activation could be histologically validated based
on b-catenin staining. Our findings demonstrate that ex
vivo NIRF imaging of an activatable cathepsin probe reli-
ably detects and quantifies tumor load and response to
EGFR inhibitor. Ex vivo NIRF imaging also detected many
small lesions that would have otherwise been difficult to
detect using conventional white light microscopy. Nonin-
vasive live animal NIRF imaging, even with attempts to
reduce abdominal background by use of liquid diets, did
not reliably discriminate AOM-induced colon tumor load
in control versus EGFR inhibitor–treated mice. More pro-
mising in vivo results were obtained with ApcMin/þ mice
versus tumor-free controls, a model with greater numbers
of tumors throughout the small intestine.
Methods and Materials
Animal Models
All studies were approved by the Institutional Animal Care
and Use Committee of the University of North Carolina at
Chapel Hill (protocol number: 10-197). KK-HIJ mice were
purchased from the Jackson Laboratory (Bar Harbor,
Maine). Twelve-week-old mice were given intraperitoneal
(IP) injections of AOM (Sigma, St. Louis, MO, Cat #
A2835; 10 mg/kg body weight) once a week for 5 weeks.
Eight weeks after first AOM injection, KK-HIJ animals
were randomly divided into control and treatment groups.
Controls were fed with regular AIN-93G diet (Research
Diets, Inc, New Brunswick, New Jersey; n ¼ 9). Mice in
the treatment group were given EGFR inhibitor premixed in
the AIN-93G diet (n ¼ 8). The EGFR inhibitor (tyrphostin)
was purchased from LC Laboratories (Cat # AG-1478;
Woburn, Massachusetts) and premixed in the AIN-93G diet
at a dose of 0.144 g tyrphostin per kg diet, which has been
shown to effectively reduce tumor load in the AOM
model.26 At 24 weeks after the first AOM injection, colono-
scopy was performed to verify the presence of tumors and
mice were injected with ProSense 680 probe for in vivo and
ex vivo imaging as described in Figure 1A. ApcMin/þ mice
on a C57BL6 background were purchased from the Jackson
Laboratory and the colony was maintained in our specific
pathogen-free facility. At 16 to 20 weeks of age when
ApcMin/þ mice reliably develop multiple small intestinal
adenomas,27 they were injected with ProSense 680 probes
and used in imaging experiments.
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Colonoscopy
Colonoscopy (n ¼ 3 for regular chow diet group and n ¼ 4 for
EGFR inhibitor diet group) was performed between 23 and 24
weeks after the first AOM injection (Figure 1A). Mice were
fasted overnight before colonoscopy to eliminate colonic stools.
During the colonoscopy, the mice were anesthetized with 1.5%
to 2% isoflurane and 3 to 4 cm of the colon from the anal verge
was visualized after inflation of the colon with air. A “Coloview
system” (Karl Storz Veterinary Endoscopy, Goleta, CA) was
used to visualize tumors. The colonoscopic images were digi-
tally recorded on an AIDA Compaq PC, Palo Alto, CA.
Near-Infrared Fluorescence Molecular Imaging
Protease-activatable NIRF imaging probe, ProSense 680 (Per-
kinElmer, Waltham, Massachusetts) was used for NIRF ima-
ging. These probes are optically silent until cleaved and
activated in vivo by proteases, such as cathepsin B, L, S, and
plasmin with reportedly highest specificity for cathepsin B.18
The 680 probe fluorophore is excited at 680 + 10 nm and
emits fluorescence at 700+ 10 nm. ProSense 680 was given
via retro-orbital injections under 2% isoflurane anesthesia,
24 hours prior to imaging, according to the manufacturer’s
instructions (PerkinElmer). Each probe was diluted in
Figure 1. Epidermal growth factor receptor (EGFR) inhibitor diet feeding reduced number and size of polypoid tumors in azoxymethane
(AOM)-treated KK-HIJ animals. A, Scheme of AOM treatment in KK-HIJ mice. B, Representative photographs of colon of chow or EGFR
inhibitor diet–fed animals visualized by colonoscopy. C, Representative white light photographs of fresh whole colon from chow or EGFR
inhibitor diet–fed animals. Small lesions (small tumors or lymphoid aggregates) are indicated by white arrows. D, Scatter plot of tumors/lesion
size in chow or EGFR inhibitor diet–fed animals. Each yellow dot represents individual tumor/lesion. n ¼ 8 to 10/group.
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1 phosphate-buffered saline (PBS) before injection and
administered using the recommended dose of 2 nmol (100
mL) per mouse.
Ex Vivo 2-D FRI Imaging
Fluorescence reflectance imaging was carried out using 2-D
imaging mode in the FMT 2500 fluorescence tomography ima-
ging system (PerkinElmer) to detect and quantify activated
probe on dissected colon. Regions of interest (ROIs) were placed
on the entire distal colon in KK-HIJ mice or entire intestine
(small intestine and colon) in ApcMin/þ mice and fluorescence
intensity was calculated (in counts/energy). Total counts/energy
for entire distal colon and for individual lesions was assessed on
dissected colon tissues from each AOM-treated mouse.
In Vivo 3-D Imaging
Both KK-HIJ mice and ApcMin/þ mice were given liquid diet
(Nestle Nutrition, Minnetonka, Minnesota; Nutren 1.0
Fiber:dH2O ¼ 1:1) instead of normal solid chow for 4 days
before in vivo imaging to clear the bowel of solid fecal matter,
which is a source of autofluorescence at NIRF wavelengths.28
Liquid diet was prepared fresh daily and given ad libitum in
mouse feeding bottles (Cat # 9019 and 9015; Bio-Serv, French-
town, New Jersey). The mice were housed in cages with wire
mesh bottoms to prevent coprophagia. Water was provided ad
lib throughout the period of liquid diet feeding.
For in vivo 3-D fluorescence tomography imaging, mice
were anesthetized with Nembutal (50 mg/kg body weight, IP)
and abdominal and torso hair was removed using Nair lotion
(Ovation Pharmaceuticals Inc, Deerfield, Illinois) to permit
light transmission. Anesthetized mice were then carefully posi-
tioned into the imaging cassette and placed into the imaging
chamber of the FMT 2500 LX system (PerkinElmer). For 3-D
tomography imaging, this system uses the NIR laser diode to
conduct a transillumination raster scan through the body of the
mouse. A thermoelectrically cooled charge-coupled device
(CCD) camera with corresponding optical filters collects both
excitation and emission NIR fluorescence. The entire image
acquisition sequence takes approximately 3 to 5 minutes per
mouse. A built-in reconstruction algorithm then reconstructs
the 3-D distribution of light source and provides spatial quan-
tification of the fluorophore.
The 3-D ROI analysis quantified fluorochrome in the colon
or the entire abdominal area of each mouse (ROI volumes are
the same across the animals). A threshold was applied to all
animals equal to 30% of the mean signal intensity in ROIs of
water control mice as reported in previous studies.14 Total
amount of fluorochrome in the target ROI was then automati-
cally calculated from the reconstructed images using True-
Quant Imaging Software (Ver. 2.0.0.19) based on preacquired
calibrations with phantoms containing known amounts of acti-
vated probe. Data are expressed as absolute total pmol of acti-
vated fluorescent probe per animal.
Dual-Imaging by Micro Computed Tomography and 3-D
Fluorescence Imaging
As a potential strategy to improve the detection of the spatial
distribution of fluorescent signal from 3-D fluorescence tomo-
graphy imaging, multimodality imaging with contrast-
enhanced computed tomography (CT) and FMT imaging was
performed on ApcMin/þ mice. Mice were injected with Pro-
Sense 680 probes 24 hours before imaging, as described above.
Iodine-based CT contrast agent (iohexol [300 mg-I/mL]; GE
Healthcare, Inc, Chicago, IL) was orally gavaged into mice 1.5
hours prior to CT imaging using a total volume of 0.4 mL in 2
separate gavages (30 minutes apart). Each mouse was then
placed in the FMT animal cassette and imaged using a microCT
scanner (eXplore CT120; GE Healthcare, Inc), followed by 3-
D fluorescence imaging in the same cassette. Fiducial marker
holders on the animal cassette were filled with contrast agent to
facilitate registration between CT and FMT imaging. The CT
imaging protocol used 70 keV X-ray energy level, a current of
30 mA, 100 mm isotropic resolution, and total imaging time of
5 minutes. After in vivo imaging, the animal was euthanized,
and intestine and colon were dissected for validation by ex vivo
fluorescence imaging. The CT images and FMT images were
registered based on coregistration of fiducial markers.
Tissue Collection for Quantification of Tumor Load
by Microscopy
Mice were euthanized by IP injection with Nembutal (100mg/kg
body weight) after in vivo imaging. Colon from KK-HIJ mice
and entire small intestine and colon from ApcMin/þ mice were
flushed with ice-cold 1 PBS and opened longitudinally for
quantification of tumor number and size by conventional white
light imaging using a dissecting scope followed by ex vivo NIRF
imaging to detect and quantify activated probe. After ex vivo
imaging, tumor and nontumor tissue samples were fixed in 10%
zinc formalin overnight and paraffin embedded.
Histology and Immunostaining
Zinc formalin-fixed and paraffin-embedded tumor and nontu-
mor tissue were sectioned for staining with hematoxylin and
eosin or immunohistochemistry. Immunostaining for b-catenin
was used to confirm that lesions detected based on increased
activation of NIRF probes showed the characteristic increase in
cytoplasmic and nuclear b-catenin typical of dysplasia or ade-
nomas. For b-catenin immunostaining, sections were deparaf-
finized in xylene, rehydrated in graded ethanol solutions and
subject to heat-induced epitope retrieval. This method involved
heating sections to 120C for 30 seconds and 90C for 10
seconds in citrate buffer pH 6.0 (Vector Laboratories, Burlin-
game, California). Sections were then blocked in 5% normal
goat serum (NGS) diluted in 0.05 M Tris buffer for 1 hour and
endogenous peroxidase activity was blocked in 3%H2O2 for 10
minutes at room temperature. b-Catenin antibody (Abcam,
Cambridge, MA, Cat # ab32572) was diluted (1:500) in 5%
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NGS/Tris buffer and sections were incubated with primary
antibody overnight at 4C, washed in 0.05 M Tris buffer, incu-
bated with biotinylated goat antirabbit IgG mouse (Jackson
ImmunoResearch, Cat # 111-065-144) for 1 hour at room tem-
perature, and after washing, the diaminobenzidine (DAB) reac-
tion (Invitrogen, Carlsbad, CA, Cat # 00-2014) was performed
according to the manufacturer’s protocol. After washing with
0.05 M Tris buffer, ABC (Vector Laboratories, Burlingame,
CA, Cat # PK 6100) was performed for 3 minutes before coun-
terstaining with hematoxylin. Cover slips were mounted in a
mixture of distyrene, a plasticizer, and xylene (DPX) mountant
(BDH Chemicals, Dawsonville, GA, Cat # 360294H). Photo-
graphs were acquired using a Zeiss microscope, Jena,
Germany.
Statistical Analysis
Signal intensities for activated probes were expressed as mean
+ standard error of the mean. Student’s t test was used to test
for statistical differences between signal intensities in AOM-
injected KK-HIJ mice fed chow or EGFR inhibitor diet and
between ApcMin/þmice and wild type (WT) nontumor controls.
Tumor load for each KK-HIJ or ApcMin/þmouse was calculated
as tumor size  tumor number. Simple linear regression was
used to calculate Pearson’s correlation coefficients and test for
correlations between ex vivo intestine 2-D quantification of
NIRF and in vivo 3-D quantification of abdominal signal in
the same animal. All statistical analyses were performed using
GraphPad Prism5 (GraphPad Software, Inc, La Jolla, Califor-
nia) software. A P value <.05 was considered statistically
significant.
Results
EGFR Inhibitor Diet Effectively Reduced Colonic Tumor
Number and Size in AOM-Injected KK-HIJ Animals
Deregulation of the EGFR pathway occurs in up to 50% of
CRCs, which has led to the development of numerous phar-
macological agents to block EGFR activity.29 An EGFR inhi-
bitor that targets the kinase domain of EGFR has proved
effective in the reduction of intestinal tumors in animal mod-
els.26,30 In the current study, colonic tumors were induced in
KK-HIJ mice according to previously published methods,25 as
summarized in Figure 1A. Eight weeks after the first AOM
injection, mice were fed with either normal chow or EGFR
inhibitor premixed diet for 15 to 16 weeks before colonoscopy
and imaging. Colonoscopy verified detectable colon tumors in
chow-fed mice and revealed fewer tumors in mice fed EGFR
inhibitor diet as illustrated in Figure 1B. Using the dissecting
microscope, we also observed decreased tumor number and
size in mice fed EGFR inhibitor (Figure 1 and Table 1). For
quantitative purposes, tumors visualized under the dissecting
microscope were categorized into either large (>1 mm in dia-
meter) polypoid lesions or small (1 mm in diameter) lesions.
Representative white light photographs (Figure 1C)
demonstrate multiple large polypoid tumors in chow-fed mice
and dramatically fewer large lesions in mice fed EGFR inhi-
bitor diet and this was verified across multiple animals (Fig-
ure 1D and Table 1). However, mice on EGFR inhibitor diet
had small lesions (Figure 1C, arrows) and significantly
greater numbers of these lesions than mice on chow diet (Fig-
ure 1D and Table1). Tumor load for each group of animals
was calculated by size number of visible lesions. Compared
with chow-fed KK-HIJ mice, mice on EGFR inhibitor diet had
significantly lower total polypoid tumor load (3.8 + 0.5 in
EGFR inhibitor diet group vs 11.3+ 2.1 in chow diet group,
P < .05).
Ex Vivo Detection of EGFR Inhibition or Induced
Reduction in Tumor Load by Using
Cathepsin-Activatable NIRF Probes
Ex vivo imaging was performed on whole colon of KK-HIJ
animals 24 hours after ProSense 680 probe injection. Repre-
sentative FRI images are shown in Figure 2A. Quantification
was performed on 2-D images of entire distal colon for each
animal (ROI is shown as purple rectangle). Compared with
chow diet–fed animals, significantly less total fluorescence was
detected in the colon of EGFR inhibitor diet–fed animals (Fig-
ure 2B). Comparing total tumor load versus total fluorescence
signals for each animal as shown in Figure 2C, we found that
EGFR inhibitor–fed mice had smaller tumor load and also
lower distal colon fluorescence signal (Figure 2C). This strong
correlation between distal colon tumor load and 2-D quantifi-
cation of tumor load using NIRF indicates that FRI 2-D ima-
ging validly detects tumor load differences across treatment
groups; FRI signal for each lesion was also tested for correla-
tion with tumor size (Figure 2D, chow diet group and Figure
2E, EGFR inhibitor diet group). A similar pattern was seen in
Figure 2D and E. Larger tumors show stronger FRI signals,
suggesting that FRI signals can reliably distinguish tumor size.
Consistent with the findings from colonoscopy and conven-
tional assays of tumor number and size in Figure 1, we found
that the majority of EGFR inhibitor diet–fed animals have
smaller tumor size (tumor size < 1 mm in diameter), while
80% of the lesions detected by 2-D FRI in chow diet–fed ani-
mals have large tumors (tumor size > 1 mm in diameter).
Together, these data demonstrate that ex vivo 2-D FRI for
activatable ProSense 680 has utility to validly detect the ther-
apeutic effect of a known inhibitor of tumorigenesis, EGFR
inhibitory on AOM-induced colonic tumors.
Table 1. Average Colonic Lesions in Both Chow-Diet and EGFR-
Inhibitor-Diet-Fed KK-HIJ Animals.a
Polypoid Tumors/Mouse Small Lesions/Mouse
Chow diet 4.60+ 0.9b 1.44+ 0.4
EGFRi diet 0.75+ 0.3 3.62+ 0.9b
aData are expressed as mean + standard error (SE). n ¼ 8 to 10/group
bP < .05 versus lesion number/animal in the chow diet–fed group.
Ding et al 5
Figure 2. Detection of decreased colonic tumor load in epidermal growth factor receptor (EGFR) inhibitor diet–fed azoxymethane
(AOM)-treated KK-HIJ animals by 2-D fluorescence imaging and ProSense 680 activatable probe. A, The 2-D fluorescence
reflectance imaging (FRI) images demonstrate reduced tumor load in EGFR inhibitor diet–fed animals. B, The 2-D quantification
analysis suggests significant lowered FRI signals in the colon of EGFR inhibitor diet–fed mice versus chow diet–fed animals. C, Graph
of distal colon 2-D FRI signal intensity (counts/energy) and tumor load in each animal indicates EGFR inhibitor diet–fed animals have
smaller and less colonic tumors. Each dot represents individual animal (red dots represent animals from EGFR inhibitor diet–fed
group, green dots represent animals from chow diet–fed group). D and E, Graph of 2-D FRI signal intensity (counts/energy) and
lesion size for individual lesion from chow diet–fed animals (D, green plot graph) and EGFR inhibitor diet–fed animals (E, red
plot graph).
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Ex Vivo 2-D FRI Using ProSense 680 Probe Can
Distinguish Large Tumors From Small Lesions, but Has
Limited Ability to Differentiate Small Tumors and
Lymphoid Aggregates
In the current study, we aimed to test the hypothesis that ex
vivo imaging of activatable ProSense 680 probe could detect
small tumors and distinguish benign lesions, such as lymphoid
aggregates from malignant lesions. To test this hypothesis,
individual lesions (including polypoid tumors and small
lesions) from AOM-injected KK-HIJ animals were collected
based on the signal intensity measured by ex vivo 2-D FRI
images (as shown in Figure 3A), then fixed and embedded for
histological sectioning. Cut sections were stained with b-cate-
nin antibody. Based on immunostaining as shown in Figure 3B,
and a grading system shown in Table 2, we assigned numerical
grades to normal epithelium, lymphoid aggregates, and nuclear
b-catenin-positive small adenomas and large adenomas. Fluor-
escence reflectance imaging signal intensity of each lesion was
also quantified and tested for correlation between FRI signal
intensity and the grade of each lesion (Figure 3C). We found
that the signal in lesions from category 4, which represents
large nuclear b-catenin-positive lesions (tumors), was signifi-
cantly stronger than signals from the other 3 lesion types
(Figure 3C). The FRI signal intensities from these other 3
categories were not significantly different based on 2-D FRI
quantification. This indicates that the ProSense 680 probe does
not reliably distinguish lymphoid aggregates from small tumors
if the tumor size is <1 mm in diameter.
Detection of AOM-Induced Colonic Tumors in KK-HIJ
Mice In Vivo by ProSense 680
FMT 3-D in vivo imaging with NIRF probes has the potential
benefits of deeper tissue penetration and quantification of
fluorescent signals, and it is a potential new technology for
noninvasive imaging tumor development and drug treatment
in preclinical studies or even with future enhancement in the
Figure 3. The 2-D ex vivo imaging with ProSense 680 activatable probe can differentiate large nuclear b-catenin-positive tumors versus small
lesions, but not small tumors and lymphoid follicle from normal epithelium. A, Representative 2-D fluorescence reflectance imaging (FRI) images
of lesions in each category. B, b-Catenin immunostaining photomicrographs to illustrate lesions in each category (1-4) based on the grading
scheme in Table 2. C, Scatter plot of each categorized lesion based on 2-D fluorescence signal intensity (counts/energy). *P < .05 versus
categories 1, 2 and 3.
Table 2. Lesions Were Divided Into 4 Categories Based on Histology
Observation.
Category # Histology Observation
1 Epithelial normal
2 Lymphoid follicle
3 Small lesions—nuclear b-catenin (þ)
4 Large lesions—dysplasia, nuclear b-catenin (þ)
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clinic. Previous studies have verified that activatable cathepsin-
based probes can reliably detect intestinal tumors by ex vivo
FRI.18,19,21 In the current study, we investigated whether intest-
inal tumors could be detected in vivo by FMT. We imaged each
animal’s abdominal area in both chow and EGFR inhibitor
diet–fed AOM-treated KK-HIJ mice. For in vivo quantifica-
tion, ROIs were either placed on the whole abdomen (Figure
4A) or only the distal colon area (Figure 4C). Three-
dimensional quantification analysis was performed as
described in the Methods. Quantification data from whole
abdomen or colon areas suggested that there is no significant
difference in total signal between chow diet and EGFR inhibi-
tor diet–fed animals despite major differences in tumor load
(Figure 4B, D). Although some animals having particularly
large colonic tumors (as seen under a dissecting microscope
and ex vivo FRI imaging) do show stronger signals in the distal
colon area by in vivo FMT quantification than animals that
have smaller colon tumors, we did not observe intense and
localized activated signals in the ROI. This suggests that non-
specific signals confound in vivo FMT-based detection and
quantification of colon tumors. Nonspecific signals could be
generated from various sources including fecal contents,
enzyme activation by skin, metabolized probe, or signal due
to probe concentrated in the liver and bladder. Software avail-
able with the FMT 2500 imaging system does not yet permit
selection of ROI to specifically image the colon. These data
suggest limitations of both FMT technology and ProSense 680-
activatable probe for in vivo detection of mouse colon tumors.
Detection of Intestinal Tumor In Vivo by ProSense
680 Probe in ApcMin/þ Mice
We used ApcMin/þ mice to further investigate the ability of
molecular probes to detect intestinal tumors in vivo because
this mouse model spontaneously develops fifty to hundreds of
small intestine adenoma polyps after the age of 120 days.31 We
took advantage of the large tumor load in this mouse model and
hypothesized that in vivo 3-D fluorescence imaging with the
FMT system may detect the large tumor load in the small
intestine. The 3-D fluorescence images obtained by the FMT
2500 system at 680 excitation wavelengths are shown in Figure
5A. We found that enzyme activation for ProSense 680 probes
Figure 4. Three-dimensional (3-D) in vivo fluorescence tomography imaging using ProSense 680 molecular probe is not effective to detect the
reduction of colonic tumor load in epidermal growth factor receptor (EGFR)-inhibitor-diet-treated azoxymethane (AOM)-injected animals. A,
Representative 3-D Fluorescence Molecular Tomography (FMT) images from chow diet– and EGFR inhibitor diet–fed animals. Region of interest
(ROI) in purple is placed in abdominal area. B, Three-dimensional (3D) quantification by FMT in abdominal area (ROI volumes are the same
across the animals) suggests no difference in fluorescence signal intensity between chow-diet and EGFR inhibitor diet–fed animals. C, Repre-
sentative 3-D FMT images from chow-diet and EGFR inhibitor diet–fed animals. Region of interest in purple is placed in the colon area. D, Three-
dimensional quantification by FMT in the colon area suggests no difference in fluorescence signal intensity between chow-diet and EGFR
inhibitor diet–fed animals.
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was higher in the abdominal area of ApcMin/þ mice than in WT
nontumor controls (Figure 5A). However, background signals
were still observed in abdominal ROI of control mice. Quanti-
fication of FMT signal demonstrated significantly higher total
signal in the abdomen of ApcMin/þ mice than control mice
(Figure 5B). After in vivo imaging, whole intestine was dis-
sected and opened for imaging ex vivo at 680 nm excitation
wavelength. Two-dimensional quantification was performed
on the whole intestine, including the small intestine and colon.
Regression analysis tested for correlations between abdominal
3-D signal intensity and whole intestine 2-D signal intensity in
each animal. As shown in Figure 5C (control mice) and Figure
5D (ApcMin/þ mice), no significant correlation was found in
ProSense 680 probe activation by these methods. This suggests
that nonspecific probe activation in the abdomen of ApcMin/þ
mice is a bias when analyzing 3-D fluorescence images
acquired from the FMT system.
In Vivo and Ex Vivo Dual-Model Imaging
To test the reliability of 3-D NIRF imaging with NIRF-
activatable probes, we performed dual modality imaging with
contrast-enhanced CT and FMT imaging, and intestinal polyps
in ApcMin/þ mouse were clearly detected in the CT images
(Figure 6A). Registration between the 2 images showed some
visual correlation between tumor location detected from
microCT and fluorescence signal from FMT imaging; how-
ever, discrepancies between fluorescence signal and tumor
detected from CT images were observed (Figure 6A, B), indi-
cating a need for improved 3-D FMT imaging and caution in
interpretation of in vivo 3-D fluorescence imaging in mouse
tumor models.
Discussion
Data from the current study support using cathepsin-activatable
probe and NIRF imaging to detect and quantify colonic tumors
and test the impact of therapeutic interventions such as EGFR
inhibitors on colonic tumor number and size in preclinical
models. The EGFR is a member of the human EGFR family
of receptor tyrosine kinases, and it has become an important
target for anticancer therapy for a variety of solid tumors,
including CRC.32-34 Previous studies have shown that both
ApcMin/þ tumors and AOM-induced tumors display increased
Figure 5. In vivo 3-dimensional (3D) fluorescence imaging using ProSense 680 activatable probe can detect abdominal tumor load in ApcMin/þ
mice. A, Representative 3-D in vivo fluorescence images of ApcMin/þmice and nontumor control mice injected with ProSense 680 probe. Region
of interest (ROI) in purple is placed in abdominal area. B, Three-dimensional quantification results in the abdominal area indicate significant
higher fluorescence signals in ApcMin/þ mice than nontumor control animals. Data are expressed as mean + standard error (SE). n ¼ 4 to 5/
group. *P < .05 versus nontumor control mice. C and D, Linear regression analysis on ex vivo 2-D whole intestine fluorescence signal intensity
and in vivo 3-D abdominal fluorescence signal intensity suggests no significant correlation in control mice (C) or ApcMin/þ mice (D).
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EGFR activity35,36 and also respond to EGFR-targeted treat-
ment.26 In the present study, we confirmed that EGFR inhibitor
dramatically reduced the number of the AOM-induced tumors.
Importantly, we demonstrate the ability of a cathepsin-
activatable NIRF probe to detect and quantify the effect of
EGFR inhibitor on tumors by ex vivo FRI imaging. The current
challenge for the traditional white light colonoscopy is detect-
ing flat tumors and small tumors to improve diagnosis and
lower the miss rate. Recent studies8,18,37 targeting imaging flat
colonic tumors indicated improved detection combining white
light and NIRF endoscopy. Our preliminary data also indicate
the potential of using cathepsin-based activatable probes to
detect flat tumors in a colonic tumor mouse model (data not
shown). To date, however, the ability of NIRF imaging with
activatable NIRF probes to reliably detect small tumors (tumor
size < 1 mm in diameter) is not established. Two very recent
preclinical studies19,13 aimed to validate the NIR endoscopy
platform to detect small colonic tumors and could only detect
tumors larger than 1 mm. To our knowledge, our data is the first
to show that cathepsin-activatable probe can detect small
tumors in the colon by ex vivo FRI but still has limited capa-
bility to validly distinguish small tumors from lymphoid aggre-
gates or normal mucosa. This is based on grouping all the
lesions into 4 categories based on histology, as shown in Figure
3, and the signal intensity in individual lesions by 2-D quanti-
fication. We found that the signal intensities of small tumors
(verified by b-catenin staining) are not different from those of
lymphoid aggregates or normal mucosa. Thus, currently, it is
not possible to validly distinguish small neoplastic lesions from
nonneoplastic lesions using FMT imaging system and
cathepsin-activatable probe without follow-up histology.
The use of NIRF-activatable probes has the potential advan-
tages of deep tissue penetration and higher target to back-
ground ratio. Unlike many other imaging modalities, optical
imaging does not rely upon ionizing radiation to generate
images, opening the way for low-risk screening applications
in clinic.38 Also, the technique that uses 3-D reconstruction is
superior to reflectance imaging (2-D FRI) because 3-D FMT
can actually quantify the accumulation of molecules in the
target.39 With all of these potential advantages of NIRF ima-
ging technology, we hypothesized that FMT imaging with
NIRF probes could give a better view of intestinal tumors in
vivo; however, we did not see high fluorescent signal localized
to tumors in the colon by in vivo imaging. The failure of in vivo
fluorescence imaging in our study can be attributed to the
following 2 major reasons: (1) the nonspecific activation of the
fluorescence probe injected in vivo causes a high level of non-
specific background signal and (2) less than ideal 3-D fluores-
cence imaging reconstruction algorithms, which cannot
successfully estimate true signal intensity and location. Several
publications using NIRF probes (660 nm excitation wavelength
and 730 nm emission wavelength) have shown probe biodis-
tributions and demonstrated normal that liver, skin, kidney and
bladder can have high fluorescence signal intensity comparable
to tumors or targeted tissue.39,40 For example, the cathepsin B-
based activatable probe (ProSense 750) has been shown to be
highly activated in normal organs such as skin, liver, kidney
and bone17 and not just esophageal adenocarcinoma during
upper gastrointestinal (GI) endoscopic examinations. There-
fore, protease enzyme activation of ProSense probes in non-
specific organs, most notably bladder, kidney, and skin, largely
contributes to the background signal when performing nonin-
vasive in vivo imaging. Consistent with these other reports, in
the present studies, the specificity of the NIRF 680 probe for
colonic tumor detection was significantly compromised due to
high background signals. Given this evidence, more specific
activatable probes that are only activated in tumors need to be
developed. Current algorithms are unable to correct the effects
of attenuation and scattering of light penetrating through tissue
and thus cannot successfully estimate true signal intensity and
location, especially when the sources of the signals are weaker
and deeper in the body. We have observed that the FMT 2500
system does much better job in reconstructing signals from
superficial locations than signals from deeper within the body.
Figure 6. Dual-model microCT/FMT imaging on intestinal adenomas in ApcMin/þ mice. A, Tumor nodules were detected by contrast-enhanced
microCT imaging (white arrows). B, Coregistration of microCT image with 3-dimensional (3D) fluorescence image activated by ProSense 680
probe. Three-dimensional image was taken at 24 hours after injection of ProSense 680 activatable probe and fused with microCT image for
anatomical colocalization. C, Two-dimensional fluorescence reflectance imaging (FRI) images of small intestine. After coregistration of in vivo
imaging, the small intestine was dissected and imaged ex vivo by FRI for validation.
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The 3-D fluorescence imaging field has been continuously
developing since the FMT 2500 system was put on the market
in 2009. More 3-D optical imaging algorithms are being devel-
oped to make the signal estimation more robust and accurate
with less error.41,42 Our results suggest that caution should be
used when interpreting in vivo 3-D optical results from the
FMT 2500 system. Another factor that could mask the true
fluorescent signal is bowel fecal content and food, which could
generate an autofluorescent background when using in vivo
nonendoscopic imaging. Previously, we observed that feces
and food in the GI tract generate strong autofluorescent signals
when imaged at 660 nm excitation wavelength (unpublished).
We also imaged liquid diet ex vivo and showed minimum
fluorescent signal, suggesting that feeding animals with liquid
diet could lower autofluorescence in the GI tract. We further
compared in vivo abdominal images from chow-fed animals
with those from liquid diet–fed animals and found, in the latter
animals, a significantly reduced whole abdomen signal inten-
sity after giving cathepsin-activatable ProSense 680 probe
injections, which demonstrated that 4 days of liquid diet feed-
ing is sufficient to reduce the GI background during in vivo
imaging. However, in the current study, animals were fed
liquid diet for 4 days before in vivo imaging and the signals
from activated probes in the tumors were still not strong
enough to be differentiated from the surrounding nonspecific
background signals, suggesting low resolution and low speci-
ficity of NIRF-activatable probes to detect spontaneous and
sporadic intestinal tumors in vivo.
As reported previously, FMT imaging with NIRF probes is
highly sensitive, but its spatial resolution is low.40 Computed
tomography has some benefits in high resolution and 3-
dimensional reconstruction of tissue of interest, but its inher-
ently low sensitivity results in poor soft tissue contrast.43
Therefore, development of 3-D fluorescence imaging/microCT
dual-model imaging with combined structural and functional
information can be complementary for both imaging modal-
ities.44 In the current study, we coregistered FMT images with
microCT images to optimize a better noninvasive imaging
model in detecting intestinal tumors in vivo. As shown in Fig-
ure 6, an added advantage of FMT-micro-CT compared to
standard FMT is that the 3-D distribution of activated probes
can be evaluated in much more detail. We observed only slight
overlap between FMT fluorescent images and microCT
images, which is problematic when attempting to use FMT to
detect tumors in vivo. With the advantage of high resolution,
micro-CT detected more tumors than NIRF imaging with acti-
vatable probes. Several previous publications suggested suc-
cess of NIRF scope to visualize tumors from inside the GI
tract10,12,13,17,18; however, this is an invasive method that can
cause damage and is not suitable for patients who are unable to
be sedated. As discussed previously, our noninvasive NIRF
imaging method has limitations in visualization and quantifica-
tion of intestinal tumors.
In conclusion, our results support the use of cathepsin-
based-activatable probes in colon tumor detection by ex vivo
NIRF imaging. Data presented here allow us to suggest that ex
vivo NIRF imaging of cathepsin activity can potentially pro-
vide a rapid and objective method to monitor the effects of
drugs on intestinal or colon tumors, particularly large tumors.
However, our data also indicate the inability of activatable
probes to differentiate between small adenomas and lymphoid
aggregates or normal mucosa without histological follow-up.
Our data also indicate some limitations of using real-time live
animal FMT imaging as a nonendoscopic method for sporadic
and spontaneous intestinal tumor detection. As it was used in
our study, in vivo FMT is not a practical technique for non-
invasive in vivo tumor detection and characterization. How-
ever, combining live animal FMT of intestinal tumors with
other imaging modalities, such as microCT, may bring about
an improvement in overall specificity and sensitivity of tumor
detection.
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